Exact Therapeutics Doses First Patient in Phase 2 Pancreatic Cancer Trial
EXACT Therapeutics has initiated its Phase 2 ENACT trial, evaluating Acoustic Cluster Therapy (ACT) combined with standard chemotherapy in...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Artificial Intelligence in Clinical Trials Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
EXACT Therapeutics has initiated its Phase 2 ENACT trial, evaluating Acoustic Cluster Therapy (ACT) combined with standard chemotherapy in...
Terns Pharmaceuticals announced data from a completed Phase 1 study and full enrollment of its Phase 2 FALCON trial...
iMDx (Nasdaq: IMDX) announced positive results from a head-to-head study comparing its flagship digital PCR-based dd-cfDNA test kit, GraftAssureIQ,...
Sana Biotechnology announced six-month follow-up results from a first-in-human study transplanting HIP-modified (hypoimmune) allogeneic islet cells (UP421) into a...
Revolution Medicines received Breakthrough Therapy Designation from the FDA for daraxonrasib, its RAS(ON) inhibitor, targeting previously treated metastatic pancreatic...
Cue Biopharma received positive Pre-Investigational New Drug (Pre-IND) feedback from the FDA for CUE-401, a first-in-class bispecific molecule designed...
BioVie Inc. announced that a poster detailing the decentralized design and patient experience of its Phase 2 SUNRISE-PD clinical...
Inventprise, a clinical-stage vaccine company, published preclinical study results in Vaccine Journal demonstrating the potential of their bivalent SARS-CoV-2...
Actuate Therapeutics announced positive results from a Phase 2 trial of elraglusib combined with gemcitabine/nab-paclitaxel (GnP) as a first-line...
Veru Inc. announced positive topline results from the maintenance extension of its Phase 2b QUALITY clinical trial for enobosarm....